Trend analysis as per recent USFDA guideline [Bioanalytics]

posted by dshah – India, 2020-08-01 07:32 (88 d 02:54 ago) – Posting: # 21815
Views: 2,077

Dear All!

If we consider the recent FDA guideline or ICH M10, i believe trend analysis for IS response, CC and QCs is also required. FDA does ask if there is upward or downward trend observed. The important point for SOP of CRO should be - allowed limit for IS response. If this not limited for that 3 subjects, then i believe CRO's practice and SOP needs to be revised.

Regards,
Dshah


Edit: Guidelines linked. [Helmut]

Complete thread:

Activity
 Admin contact
21,179 posts in 4,414 threads, 1,474 registered users;
online 7 (0 registered, 7 guests [including 3 identified bots]).
Forum time: Wednesday 09:26 CET (Europe/Vienna)

Actually, science starts to become interesting
only where it ends.    Justus von Liebig

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5